VIRX

Viracta Therapeutics Inc

VIRX, USA

Viracta Therapeutics, Inc., a clinical-stage precision oncology company, focuses on the treatment and prevention of virus-associated cancers that impact patients worldwide. The company's lead product candidate is Nana-val, an all-oral combination therapy of its proprietary investigational drug, nanatinostat, and the antiviral agent valganciclovir. It's Nana-val is in various ongoing clinical trials, including NAVAL-1, an open-label Phase 2 basket trial for the treatment of multiple subtypes of relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's product pipeline also includes vecabrutinib, a clinical-stage product candidate; and VRx-510, a preclinical product candidate. The company is headquartered in Cardiff, California.

https://www.viracta.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
VIRX
stock
VIRX

Oncology Biotech Viracta Collapses: Development Programs Halted as Company Shuts Down Stock Titan

Read more →
VIRX
stock
VIRX

Viracta Therapeutics to be delisted from Nasdaq Investing.com

Read more →

Showing 2 of 9

Analyst Ratings & Sentiment

(Last Updated 2024-09-30)

Rating:

HOLD

Target Price:

$3

Analyst Picks

Strong Buy

0

Buy

0

Hold

1

Sell

0

Strong Sell

0

Finn Analysis

(Last Updated 2024-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-0.06

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very High

159.48 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-48.06 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 15.61% of the total shares of Viracta Therapeutics Inc

1.

Citadel Advisors Llc

(3.8251%)

since

2024/09/30

2.

Vanguard Group Inc

(2.4016%)

since

2024/09/30

3.

Samsara BioCapital, LLC

(1.7354%)

since

2024/09/30

4.

Stonepine Capital Management Llc

(1.258%)

since

2024/09/30

5.

LAURION CAPITAL MANAGEMENT LP

(0.8358%)

since

2024/09/30

6.

Aisling Capital Management LP

(0.7261%)

since

2024/09/30

7.

Vanguard Institutional Extnd Mkt Idx Tr

(0.7108%)

since

2024/12/31

8.

Geode Capital Management, LLC

(0.629%)

since

2024/09/30

9.

Renaissance Technologies Corp

(0.6174%)

since

2024/09/30

10.

BlackRock Inc

(0.5909%)

since

2024/09/30

11.

Fidelity Extended Market Index

(0.3523%)

since

2024/12/31

12.

HRT FINANCIAL LLC

(0.3493%)

since

2024/09/30

13.

LANDSCAPE CAPITAL MANAGEMENT,LLC

(0.1719%)

since

2024/09/30

14.

State Street Corp

(0.1657%)

since

2024/09/30

15.

Extended Equity Market Fund K

(0.122%)

since

2024/12/31

16.

United Capital Financial Advisers Inc

(0.1082%)

since

2024/09/30

17.

Fidelity Total Market Index

(0.1037%)

since

2024/12/31

18.

Northern Trust Corp

(0.0959%)

since

2024/09/30

19.

Morgan Stanley - Brokerage Accounts

(0.0772%)

since

2024/09/30

20.

Fidelity Series Total Market Index

(0.0716%)

since

2024/12/31

21.

Goldman Sachs Group Inc

(0.0682%)

since

2024/09/30

22.

Integrys Wealth Advisors LLC

(0.0629%)

since

2024/12/31

23.

Vanguard Instl Ttl Stck Mkt Idx Tr

(0.0516%)

since

2024/09/30

24.

Royal Bank of Canada

(0.0503%)

since

2024/09/30

25.

NT Ext Equity Mkt Idx Fd - NL

(0.0463%)

since

2024/12/31

26.

Independent Securities BCI Wldwd Flex A

(0.0453%)

since

2024/04/30

27.

Northern Trust Extended Eq Market Idx

(0.0452%)

since

2024/12/31

28.

NT Ext Equity Mkt Idx Fd - L

(0.0452%)

since

2024/12/31

29.

WEALTHTRUST AXIOM LLC

(0.0413%)

since

2024/09/30

30.

Bank of America Corp

(0.0379%)

since

2024/09/30

31.

NT Ext Equity Mkt Idx Fd - DC - NL - T2

(0.0367%)

since

2024/12/31

32.

Spartan Total Market Index Pool E

(0.0213%)

since

2024/12/31

33.

State St US Extended Mkt Indx NL Cl C

(0.017%)

since

2024/12/31

34.

Vanguard U.S. Eq Idx £ Acc

(0.0168%)

since

2024/12/31

35.

Extended Equity Market Fund M

(0.0158%)

since

2024/12/31

36.

Spartan Extended Market Index Pool E

(0.0148%)

since

2024/12/31

37.

BNYM Mellon SL Market Completion UC1

(0.0121%)

since

2024/12/31

38.

NT Ext Eq Mkt Indx Fd DC Lend T3

(0.0108%)

since

2024/12/31

39.

NT Ext Eq Mkt Indx Fd DC Lend T4

(0.0108%)

since

2024/12/31

40.

NT Ext Eq Mkt Indx Fd DC Lending Tier 5

(0.007%)

since

2024/09/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

0

EPS Estimate

-0.17

EPS Difference

0.17

Surprise Percent

100%

Investing Fit Scorecard

(Last Updated 2024-09-30)

Deep Value
Weak Deep Value(2.5)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2)
Growth
Weak Growth Prospect(2)
Momentum
No Momentum(2.5)
Net Net
Not Undervalued (Net-Net)(2)
Quality
Low Quality Business(3)
Value
Overpriced(3)

Income Statement

(Last Updated 2024-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2024-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2024-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.